5-chloro-2-(2-fluorophenyl)-1-propyl-1H-benzo[d]imidazole | 1415488-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-chloro-2-(2-fluorophenyl)-1-propyl-1H-benzo[d]imidazole
• 英文别名: 5-Chloro-2-(2-fluorophenyl)-1-propylbenzimidazole；5-chloro-2-(2-fluorophenyl)-1-propylbenzimidazole
• CAS: 1415488-76-4
• 化学式: C₁₆H₁₄ClFN₂
• 分子量: 288.752
• InChiKey: RJMMJHBJXCBJNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,5-二氯硝基苯 在 sodium dithionite 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 5-chloro-2-(2-fluorophenyl)-1-propyl-1H-benzo[d]imidazole
  参考文献：
  名称：

  Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine Derivatives

  摘要：

  Sepsis, an acute inflammatory disease, remains the most common cause of death in intensive care units. A series of benzimidazole and imidazopyridine derivatives were synthesized and screened for anti-inflammatory activities, and the imidazopyridine series showed excellent inhibition of the expression of inflammatory cytokines in LPS-stimulated macrophages. Compounds X10, X12, X13, X14, and X15 inhibited TNF-alpha and IL-6 release in a dose-dependent manner, and X12 showed no cytotoxicity in hepatic cells. Furthermore, X12 exhibited a significant protection against LPS-induced septic death in mouse models. Together, these data present a series of new imidazopyridines with potential therapeutic effects in acute inflammatory diseases.

  DOI：

  10.1021/ml300282t

文献信息

• Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine Derivatives
  作者：Gaozhi Chen、Zhiguo Liu、Yali Zhang、Xiaoou Shan、Lili Jiang、Yunjie Zhao、Wenfei He、Zhiguo Feng、Shulin Yang、Guang Liang

  DOI：10.1021/ml300282t

  日期：2013.1.10

  Sepsis, an acute inflammatory disease, remains the most common cause of death in intensive care units. A series of benzimidazole and imidazopyridine derivatives were synthesized and screened for anti-inflammatory activities, and the imidazopyridine series showed excellent inhibition of the expression of inflammatory cytokines in LPS-stimulated macrophages. Compounds X10, X12, X13, X14, and X15 inhibited TNF-alpha and IL-6 release in a dose-dependent manner, and X12 showed no cytotoxicity in hepatic cells. Furthermore, X12 exhibited a significant protection against LPS-induced septic death in mouse models. Together, these data present a series of new imidazopyridines with potential therapeutic effects in acute inflammatory diseases.